Emerging Perspectives in Vitiligo: Pathogenesis, Treatment, and Biomarker Development

Vitiligo is unpredictable and impactful. Though clinically characterized by noninflamed depigmented patches on skin with absent melanocytes, a lot goes behind the curtains, especially with respect to immune activation. Various hypotheses have been proposed so far, and it seems all those have some part to play including genetic susceptibility, environmental influence, oxidative stress, and melanocytorrhagy; ultimately leading to immune dysregulation and T-cell activation further orchestrating selective elimination of melanocytes coupled with defective melanocyte regeneration.[1] Vitiligo is now considered a prototype of tissue-specific autoimmunity. The three articles featured in this issue throw light on the contemporary vitiligo research and discuss complexities of real-world phototherapy practice, cellular mechanisms of how phototherapy works, and biomarkers of active vitiligo.[2-4] These articles illustrate how the field is slowly evolving toward a more biologically informed approach to management of vitiligo, similar to what is happening in dermatology and the clinical world as a whole. Narrowband ultraviolet B (NBUVB) phototherapy continues to be one of the most effective and widely utilized therapies for vitiligo.[1] Even the advent of Janus kinase (JAK) inhibitors has not changed this. Little information exists regarding how providers actually administer phototherapy in day-to-day practice. This requires balancing evidence-based recommendations and standardized protocols with practical issues, for example, patient preferences including travel and time constraints, and resource limitations. The nationwide survey study in India by Vendhan and Mysore[2] provides valuable data regarding real-world NBUVB utilization among Indian dermatologists. Importantly, most providers recalled favorable outcomes for their practices, with early improvement typically observed after 10–20 treatment sessions. Substantial repigmentation occurred after 50–70 sessions, suggesting a population-level effectiveness of NBUVB. The authors did note variability in starting doses, minimal erythema dose testing, dose-escalation schedules, maintenance treatments, and management of interrupted treatments. The authors suggest an important recommendation for providers and practices- standardization of phototherapy protocols can facilitate multicenter research and promote more consistent clinical care. Repigmentation is one of the most important outcomes in vitiligo. However, stabilization of diseases activity is almost equally important. Durable repigmentation in vitiligo depends upon activation of melanocyte stem cell reservoirs within hair follicles and their subsequent migration into depigmented epidermis. Phototherapy has long been used as a dual-action treatment facilitating control of disease activity and repigmentation. Following regenerative approaches used to restore melanocytes in stable vitiligo, for example, vitiligo surgeries like melanocyte-keratinocyte epidermal cell/hair follicle suspensions; many providers prefer to add postprocedural phototherapy/immunosuppressives. For example, cyclosporine or a combination of both phototherapy and immunosuppression is prescribed for some time to abort the cytotoxic responses that could thwart the uptake of the grafted cells and also simultaneously facilitate the production and movement of melanocytes.[5] In this issue, the translational study by Dutta et al.[3] provides mechanistic insights into how NBUVB induces repigmentation. Using paired lesional and control biopsies from patients undergoing NBUVB monotherapy, Dutta et al.[3] demonstrate restoration of epidermal melanocytes, increased melanin production, upregulation of melanocyte differentiation and melanogenesis genes, and reduction of skin-resident T cells. This study reinforces the concept that successful vitiligo therapy requires addressing both immune activation and melanocyte regeneration.[6] Activity and extent of vitiligo are commonly measured by vitiligo outcome assessment tools. One may have extensive vitiligo but minimal activity or vice versa. The implication of this is when to use immunosuppressants. Though NBUVB functions as both stabilizing and repigmenting treatment, many patients will not stabilize with NBUVB alone and end up needing immunosuppressants like steroids, JAK inhibitors, and others. Stabilization is as important as repigmentation, as it limits the extent of the final area that needs repigmentation, especially for sites known to repigment poorly. The clinical success of JAK inhibitors provides compelling clinical evidence that precise interruption of involved immune circuits can also induce meaningful repigmentation, more so when combined with phototherapy. The study by Ismail et al.[4] addresses objective biomarkers of vitiligo activity. Authors demonstrate significantly elevated serum CXCL10 levels in patients with active nonsegmental vitiligo (demonstrating clinical and dermoscopic markers of activity including poorly defined borders, absent perifollicular pigmentation, and micro-Koebnerization) compared with healthy controls and patients with stable vitiligo. Importantly, correlation of serum CXCL 10 level was much stronger with disease activity than disease extent. This finding further strengthens the role of CXCL10 and IFN-γ–CXCL10–CXCR3 axis as an objective and dynamic biomarker of ongoing immune activation in vitiligo (rather than cumulative depigmentation burden), which may be amenable to the usage of immunosuppressives guiding earlier intervention.[7,8] Together, the studies featured in this issue collectively move the field closer to the ultimate goal of vitiligo research—restoring pigment, restoring immune homeostasis, and achieving practical and durable repigmentation and disease stabilization—and reinforce that further advances in vitiligo are likely to arise from the integration of diverse scientific approaches.[9] Use of artificial intelligence (AI) The preparation of this manuscript was carried out entirely by the authors without the use of artificial intelligence technologies.